

1 **Prediction of human intestinal absorption using micellar liquid chromatography**
2 **with an aminopropyl stationary phase**

3 Dina S. Shokry², Laura J. Waters*¹, Gareth M. B. Parkes¹, John C. Mitchell²

4 ¹ School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, HD1
5 3DH, UK,

6 ² School of Engineering and Science, Medway Centre for Pharmaceutical Science, University
7 of Greenwich, Chatham, Kent ME4 4TB, UK.

8 *Corresponding author: l.waters@hud.ac.uk

9 **Abstract:**

10 The extent of human intestinal absorption (HIA) for a drug is considered to be an important
11 pharmacokinetic parameter which must be determined for orally administered drugs.
12 Traditional experimental methods relied upon animal testing and are renowned for being time
13 consuming, expensive as well as being ethically unfavourable. As a result, developing
14 alternative methods to evaluate a drug's pharmacokinetics is crucial. Micellar liquid
15 chromatography (MLC) is considered to be one of these methods that can replace the use of
16 animals in prediction of HIA. In this study, the combination of an aminopropyl column with
17 the biosurfactant sodium deoxycholate (NaDC) bile salt were used in the experimental
18 determination of micelle-water partition coefficients ($\log P_{mw}$) for a group of compounds.
19 Multiple linear regression (MLR) was then used for the prediction of HIA using the
20 experimentally determined $\log P_{mw}$ along with other molecular descriptors leading to the
21 construction of a model equation of $R^2= 85 \%$ and a prediction power represented by $R^2_{Pred.}$
22 $=72 \%$. The use of MLC with an aminopropyl column in combination with NaDC was found
23 to be a good method for the prediction of human intestinal absorption, providing data for a far
24 wider range of compounds compared with previous studies.

25
26
27 **Keywords:**

28 Aminopropyl column; biosurfactant; human intestinal absorption; micellar liquid
29 chromatography; multiple linear regression; pharmacokinetics; sodium deoxycholate.

30
31
32
33

34 **1.Introduction:**

35 The use of micelles in HPLC was first introduced by Armstrong and Henry in 1980 (Berthod
36 and Garcia-Alvarez-Coque 2000), now more commonly known as micellar liquid
37 chromatography (MLC), and was used to enhance retention and selectivity of various solutes
38 that would otherwise be inseparable or poorly resolved. MLC is an interesting technique for
39 green chemistry as it uses a mobile phase containing 90 % or more water, these micellar mobile
40 phases have low toxicity, are non-flammable and do not produce hazardous waste (Kanakaiah
41 2013). Micellar liquid chromatography uses mobile phases containing a surfactant (ionic or
42 non-ionic) above its critical micellar concentration (CMC) along with columns such as C18
43 (and to a lesser extent cyanopropyl (CN)) (Kalyankar, Kulkarni et al. 2014; Rambla-Alegre
44 2012). In MLC, surfactant monomers incorporated in the mobile phase adsorb on the porous
45 RPLC packing altering the various surface properties of the stationary phase, such as surface
46 area, polarity, structure, and pore volume which majorly influences chromatographic retention.
47 The stationary phase pores are also coated by the surfactant molecules, decreasing their volume
48 (Kalyankar, Kulkarni et al. 2014). Different stationary phases have different chemical
49 characteristics which influence the elution of different groups of compounds where the
50 formation of an aqueous layer over the stationary phase depends on the nature and the number
51 of the chemically bonded groups therefore, determining the solutes' partitioning. As a result,
52 the use of a aminopropyl column was attempted in this work to help enhance the applicability
53 of chromatography for absorption prediction where higher reactivity and polar interactions are
54 important characteristics of amino columns as discussed in literature (Rambla-Alegre, Carda-
55 Broch et al. 2009; Gama, da Costa Silva et al. 2012).

56 MLC has been applied to a variety of applications including prediction of transdermal
57 permeation (Waters, Shahzad et al. 2013) through to oral drug absorption (Escuder-Gilabert,
58 Martinez-Pla et al. 2003), blood brain barrier penetration (Escuder-Gilabert, Molero-Monfort
59 et al. 2004) and ocular tissue permeability (Martin-Biosca, Molero-Monfort et al. 2003). In
60 recent years, studies have also attempted to link chromatographically derived retention
61 constants with pharmacokinetic predictors determined *in silico* and although linear
62 relationships have been found (Milošević, Stojanović, Penov-Gaši, Perišić-Janjić, Kaliszan
63 2014), these previously published studies depend upon the reliability of calculated data whereas
64 this work attempts to correlate chromatographic data with published experimental data. Solutes
65 injected within an MLC system are classified according to their elution behaviour into three
66 categories; binding, antibinding and non-binding. Binding solutes are those which bind or

67 associate to micelles, they show decreased retention when the micelle concentration is
68 increased. Antibinding solutes display increased retention with an increased concentration of
69 micelles. Finally, non-binding solutes do not bind or associate to micelles displaying unaltered
70 retention with changing micellar concentration.

71 Previous work by the authors of this study presented the application of a cyanopropyl column
72 as a stationary phase in an MLC system using a mixture of bile salts to determine human
73 intestinal absorption (HIA) (Waters, Shokry et al. 2016; Shokry, Waters et al. 2018). However,
74 for this study, an aminopropyl column was investigated as the stationary phase to determine
75 the suitability of this alternative column for facilitating prediction of HIA.

76 In summary, the work presented in this paper utilises micellar liquid chromatography to predict
77 human intestinal absorption with sodium deoxycholate as the mobile phase and an aminopropyl
78 column as the stationary phase. Previous studies have successfully utilised a system similar to
79 this yet have been restricted by the variety of compounds that can be analysed based upon
80 limitations as a consequence of the stationary phase employed. Through incorporating an
81 aminopropyl column in to the system it is envisaged that a far wider range of compounds will
82 be suitable for analysis thus expanding the potential applicability of the technique.

83 **2. Materials and Methods**

84 **2.1 Materials**

85 Sodium deoxycholate (NaDC) was used as purchased from Sigma Aldrich, Dorset, UK (97 %).
86 Analysed compounds using MLC were acetaminophen (99 %, Sigma Aldrich, Dorset, UK),
87 acetyl salicylic acid (99 %, Acros organics, Geel, Belgium), caffeine (97 %, Sigma Aldrich,
88 Dorset, UK), carbamazepine (99 %, Sigma Aldrich, Dorset, UK), cimetidine (Sigma Aldrich,
89 Dorset, UK), diclofenac (98 %, TCI, Zwijndrecht, Europe), fenoprofen (97 %, Fluka, Dorset,
90 UK), fluconazole (98 %, Sigma Aldrich, Dorset, UK), flurbiprofen (98 %, TCI, Zwijndrecht,
91 Europe), gemfibrozil (98 %, TCI, Zwijndrecht, Europe), ibuprofen (98 %, BASF, Cheshire,
92 UK), indomethacin (99 %, Sigma Aldrich, Dorset, UK), ketoprofen (98 %, Sigma Aldrich,
93 Dorset, UK), lidocaine (98 %, Sigma Aldrich, Dorset, UK), lornoxicam (>98 %, TCI,
94 Zwijndrecht, Europe), meloxicam (98 %, TCI, Zwijndrecht, Europe), naproxen (98 %, Sigma
95 Aldrich, Dorset, UK), nicotinic acid (99.5 %, Sigma Aldrich, Dorset, UK), phenylbutazone
96 (98.5 %, Sigma Aldrich, Dorset, UK), piroxicam (98 %, Sigma Aldrich, Dorset, UK), salicylic
97 acid (99 %, Fisher Scientific, Loughborough, UK), theophylline (98 %, TCI, Oxford, UK) and
98 terbutaline (96 %, Sigma Aldrich, Dorset, UK) used as purchased. Deionised water was
99 prepared using a Barnstead™ Ultrapure system.

100 2.1 Preparation of NaDC solutions used as mobile phase:

101 A 20 mM stock solution of NaDC bile salt in water was prepared by transferring an accurately
102 weighed amount of NaDC to a 250 mL volumetric flask and completing to the mark with
103 deionised water. Accurately measured aliquots were then transferred from the stock solution to
104 50 mL volumetric flasks; solutions were then completed to the final volume with deionised
105 water to give NaDC solutions of concentrations within the range of (5-20 mM).

106 **2.2 Experimental Procedure**

107 Micellar liquid chromatography required injection of 20 μ L samples of twenty-three
108 compounds (0.2 mM) into a Rheodyne injector and pumped with the mobile phase through a
109 reversed phase aminopropyl column (APS) (Hypersil 5 μ m, 15 cm x 4.6mm, Thermo Fisher
110 Scientific, MA, USA) using an Agilent 1100 Series Binary pump at a flow rate of 1.34 mL/min.
111 The retention of the solutes within the column was detected using a UV detector (Perseptive
112 Biosystems UVIS-205, MA, USA), set at a wavelength appropriate for each drug and recorded
113 via Picolog software indicating retention times. The mobile phase was filtered through a 0.45
114 μ m Nylon filter and degassed in an ultrasonic bath. The recorded data were analysed to obtain
115 retention factors and each sample was repeated in triplicate to ensure that reasonable accuracy
116 and precision were achieved using a series of mobile phases of NaDC concentrations. A
117 minimum of five concentrations were analysed per drug ranging from 5-20 mM. All
118 experiments were performed at room temperature.

119 **2.3 Determination of Dead time (t_0)**

120 The dead time (t_0) (time taken by the solvent front to reach the detector) was measured by the
121 injection of water in to the system (Pramauro, Minero et al. 1988) for the appearance of the
122 first major perturbation to the baseline. The dead time was calculated from an average of ten
123 results.

124 **2.4 Calculation of Log P_{mw}**

125 From the recorded retention times for each compound and the dead time, retention factors (k)
126 were calculated as follows:

$$127 \quad k = \frac{(\text{Retention time} - \text{dead time})}{\text{dead time}} \quad \text{Eq. (1)}$$

128 The CMC value of NaDC was taken to be 5 mM (Olesen, Westh et al. 2015) and the micellar
129 concentration (C_M) was then calculated for each NaDC concentration used as follows:

$$130 \quad (C_M) = \text{Total surfactant concentration} - \text{Critical micellar concentration (CMC)} \quad \text{Eq. (2)}$$

131 On the basis of a linear relationship between micellar concentration (C_M) and $(1/k)$ according
132 to the equations described by Arunyanart and Love (1985), the log of the partition coefficient
133 ($\log P_{mw}$) can be determined for each compound by:

$$134 \quad \text{Log } P_{mw} = \log[\text{intercept/slope}] \quad \text{Eq. (3)}$$

135 **3. Results:**

136 Prior to this study, the use of NaDC as a mobile phase (with an alternative column) confirmed
137 the potential of MLC in the prediction of HIA (Waters, Shokry et al. 2016). A further study
138 considered the effect of changing the mobile phase composition confirming the use of a mixture
139 of NaDC along with phospholipid was a better predictive system of HIA than NaDC alone
140 (Shokry, Waters et al. 2018). This current study explores the effect of an alternative stationary
141 phase regarding HIA predictive capability.

142 **3.1 Selection of Aminopropyl column**

143 According to literature, aminopropyl columns are widely used especially in hydrophilic
144 interaction liquid chromatography (HILIC). They also offer a more reactive, selective and
145 efficient stationary phase and polar interactions are more abundant than in cyanopropyl
146 columns (Rambla-Alegre, Carda-Broch et al. 2009; Gama, da Costa Silva et al. 2012). Also
147 aminopropyl columns offer the possibility of anion exchange mechanisms around neutral pH
148 (Olsen 2001). Compounds such as amines, ethers, esters and ketones are preferentially retained
149 on amino columns compared with cyano columns. This could be the reason why more
150 compounds were analysed using this column (rather than a cyano column) in the previous
151 study. Furthermore, because of general concerns about stability and reproducibility,
152 cyanopropyl columns are less commonly used overall.

153 **3.2 Effect on retention behaviour**

154 Experimental data for the calculated $\log P_{mw}$ values, along with published physicochemical
155 data utilised for analysis are presented within 'Supplementary Information' (Table S1). The
156 use of an aminopropyl column as a stationary phase had a great impact on the retention profiles
157 for a number of the analysed compounds (including neutral, anionic and cationic compounds)
158 using MLC. Therefore, there was an appreciable effect on the obtained $\log P_{mw}$ values which
159 is a reflection of the partitioning process of the compounds under study. The dead time average
160 value was determined to be 79.40 seconds.

161 Ideally, neutral and cationic drugs are expected to show binding behaviour whilst anionic drugs
162 are expected to show antibinding behaviour with the increase in the bile salt concentration.
163 Interestingly, the opposite to what was expected was observed in that neutral compounds

164 displayed antibinding behaviour whilst cationic and anionic drugs displayed both binding and
165 antibinding behaviour according to their molecular weight.

166 **3.2.1 Theory behind retention behaviour**

167 Salt bridge formation is assumed to be the justification behind the change in the way drugs
168 interacted with the stationary phase (aminopropyl column) that led to unconventional patterns
169 of elution. This assumption is supported by the work of Takeuchi *et al.* who presented the
170 possibility of using bile acids as stationary phases in liquid chromatography through their
171 immobilisation on aminopropyl silica through electrostatic interactions (Takeuchi, Chu *et al.*
172 1998). A salt bridge is a combination of two noncovalent interactions which are hydrogen
173 bonding and electrostatic interactions. Although such bridges are abundant in protein folded
174 conformations (to provide stability) they are also found in supramolecular chemistry. Since the
175 pH of the medium was found to be in the range of (6.4-8.0) the amino group (-NH₂) is thought
176 to undergo protonation converting to the ammonium ion (-NH₃⁺) and, in this case, rendering
177 the column positively charged. As a result, a salt bridge is assumed to have formed through
178 electrostatic attraction between the negatively charged carboxylic group (-COO⁻) of NaDC and
179 the positively charged ammonium group (-NH₃⁺) of the column also, through hydrogen
180 bonding between the hydrogen atom of the ammonium group (-NH₃⁺) and the oxygen atom of
181 the carboxylic group (-COO⁻) which adds up to the overall stability of the formed network as
182 it acts as a small stabilising interaction (Anslyn and Dougherty 2006). The charge on both the
183 column and the bile salt adsorbed on its surface are masked by their electrostatic attraction.
184 Salt bridges form between the bile salt monomers and the column creating a stable network.
185 Also, hydrogen bonds form between the bile salts hydroxyl groups as well as the nonpolar
186 binding of the hydrophobic moiety of NaDC molecules, creating a network with free monomers
187 from the mobile phase leading to the formation of the appearance of bilayers of bile salt.


188 Although some anionic drugs displayed antibinding behaviour (which is typical for
189 conventional retention), a number of anionic drugs exhibited the opposite behaviour i.e. a
190 binding interaction with NaDC. Both cases can be explained according to the previously
191 mentioned theory for bile salt (micellar mobile phase) interactions with the aminopropyl
192 column used in this method.

193 The anionic drugs (fenopfen, ibuprofen, gemfibrozil and phenylbutazone) displayed a
194 retention behaviour typical for that expected for anionic compounds with anionic surfactant
195 with an antibinding interaction with the NaDC micelles. On the other hand, three anionic drugs,
196 namely lornoxicam, meloxicam and piroxicam displayed an opposite pattern of interaction as

197 they acted as binding solutes. This is unusual for anionic drugs when analysed with anionic
198 surfactants in MLC.

199 The typical antibinding behaviour of anionic compounds can be attributed to the electrostatic
200 repulsion taking place between the negatively charged compounds and the negatively charged
201 surfactant. As a result of this repulsion the compound bound to the column displayed an
202 increase in retention on the column with the increase in the surfactant concentration. In this
203 case the drug must have a low molecular weight in order to be entrapped inside the layers of
204 the bile salt network structure formed with the aminopropyl column by means of electrostatic
205 attraction and hydrogen bonding. As a result, fenoprofen, ibuprofen, gemfibrozil and
206 phenylbutazone, having relatively low molecular weights of 242.3, 206.3, 250.3 and 308.4
207 g/mol respectively (<http://www.chemspider.com/>), were entrapped inside the bile salt network
208 structure displaying an antibinding interaction. However, lornoxicam, meloxicam and
209 piroxicam, having relatively higher molecular weight values of 371.8, 351.4 and 331.4 g/mol
210 respectively (<http://www.chemspider.com/>), could not be entrapped inside the bile salt network
211 structure. Instead, they were entrapped inside the micellar core, overcoming the repulsion
212 forces with the micelles as a consequence of their high molecular weights (Figure 1).

213 For neutral drugs (acetaminophen, caffeine, fluconazole and theophylline), an antibinding
214 retention behaviour was observed which is again, against convention, where neutral drugs
215 traditionally undergo a binding interaction. This can be attributed to the preference of these
216 drugs to bind to the more stable hydrophobic core of the bile salt network structure rather than
217 that of the bile salt micelles in the mobile phase. Also these drugs have comparatively low
218 molecular weights of 151.2, 194.2, 306.27, 180.2 g/mol respectively
219 (<http://www.chemspider.com/>), facilitating entrapment within the hydrophobic core of the bile
220 salt network structure within the column therefore showing antibinding retention behaviour.



221
222 **Figure 1:** Chromatograms displaying the binding behaviour of meloxicam over a series of
223 mobile phase concentrations with an aminopropyl column as a stationary phase. (The dotted
224 line is only used for visual guidance).

225 3.3 Prediction of human intestinal absorption (HIA)

226 Statistical data analysis was conducted using Minitab 17[®] software. Multiple linear regression
227 was carried out where different molecular descriptors collected from literature were regressed
228 against the dependant variable %HIA and a backward elimination modelling strategy was
229 carried out. To take variance inflation factors (VIF) to acceptable limits, variables with high
230 (VIF) were removed. Finally, an optimum model was obtained that provides a good summary
231 of data, this was undertaken in a similar manner to that previously published (Waters, Shokry
232 et al. 2016).

233 The variables remaining in the optimal model were assessed for significance and relative
234 importance by standardised coefficients and the associated p-values.

235 The predictive ability of the final model was assessed using adjusted-R² and R² for prediction
236 (R²_{PRED}) derived from predicted residual error sum of squares (PRESS statistic). The predictive
237 ability of the model was indicated by R²_{PRED} which consequently reflects the model's
238 applicability.

239 In this study, a group of twenty-three drugs were analysed using the MLC system using an
240 aminopropyl (APS) column and log P_{mw} was calculated for each compound, a number of
241 molecular descriptors such as molecular weight (Mwt), polar surface area (PSA), freely
242 rotating bonds (FRB), molar volume (V_M), dissociation constant (pK_a), aqueous solubility (S_w),
243 number of hydrogen bond donors (nHD) and number of hydrogen bond acceptors (nHA) were
244 used along with the obtained log P_{mw} to develop a mathematical model for prediction of %HIA.
245 Logit (%HIA) was used to improve the linear relationship between published (%HIA) and
246 experimental log P_{mw} values as seen in studies of a similar type (Norinder, Österberg et al.
247 1999; Raevsky, Fetisov et al. 2000; Zhao, Abraham et al. 2002). The human intestinal
248 absorption values were transformed to logit by substitution in Equation 4.

$$249 \text{Logit (\%HIA)} = \log (\% \text{HIA} / (100 - \% \text{HIA})) \quad \text{Eq. (4)}$$

250 For simplification, all drugs of 100 or 0 % HIA were excluded from the training set.

251 Log P_{mw} was successfully included with 2 other molecular descriptors in the final model
252 equation with %HIA experimental values for orally administered drugs which successfully
253 predicted the %HIA with 72 % predictability. The final model was validated using a set of
254 seven compounds.

255 The model obtained for the prediction of %HIA is given by Equation 5:

$$256 \text{logit \%HIA} = -0.758 - 0.369 \log P_{mw} + 0.01157 V_M + 0.0714 S_w \quad \text{Eq. (5)}$$

258 Sixteen drugs were used in the development of the final model. The model's R² = 84.62 %,

259 $R^2_{\text{adjust.}} = 80.77\%$, $R^2_{\text{PRED}} = 71.51\%$, $S = 0.203$


260 A 95 % confidence interval for $\log P_{\text{mw}}$ is given by (-0.726, -0.011), t-statistic and standardised
261 coefficient of $\log P_{\text{mw}}$ are -2.25 ($p < 0.05$) and -0.294 respectively suggesting statistical
262 significance of $\log P_{\text{mw}}$ as a predictor. Also the F-ratio of the overall model is statistically
263 significant, $F = 22$ and P value 0.000 ($p < 0.05$). Figure 2 shows no marked relationship between
264 residuals and predicted values while Figure 3 summarises the model.

265 Seven drugs (cimetidine, fenopropfen, lornoxicam, nicotinic acid, piroxicam, salicylic acid and
266 terbutaline) were used to test the model predictability. The model was able to predict the %HIA
267 for these drugs within a minimum of 0.1 % and a maximum of 8 % difference between the
268 predicted %HIA and the published %HIA. The model appears to have underestimated %HIA
269 for both lornoxicam and salicylic acid with a 12 % and 24 % difference between the two
270 predicted and published values. The relationship between the predicted and the experimental
271 %HIA values is shown in Table 1 and Figure 4.


272 Comparing this current model with that obtained with the MLC system using a cyanopropyl
273 column; $\log \text{HIA} = -0.410 - 0.482 \log P_{\text{mw}} + 0.00852 \text{Mwt} + 0.04799 S_w$ (Waters, Shokry et
274 al. 2016), it is observed that three predictors were included in each model: ($\log P_{\text{mw}}$ and S_w) in
275 both models, Mwt (in CN column derived model) and V_M (in APS column derived model).
276 According to literature, molecular weight (Mwt) and molar volume (V_M) are both estimates of
277 size however, V_M takes into consideration both the size and shape as it is very much related to
278 molecular surface area which offers a better guide to estimate the potential for permeability
279 (Smith, Walker et al. 2006). Although both models have nearly the same HIA prediction ability,
280 this current model was obtained based on a larger data set where the change of the used column
281 from CN to APS allowed the analysis of a larger number of compounds. This is because the
282 latter column resulted in compound-stationary phase interactions that facilitated calculation of
283 values for compounds that had been unsuccessfully analysed using the former column type.

284 Finally, combining the results of changing the column type from CN to APS and changing the
285 type of micellar mobile phase from NaDC to a physiological mixture of bile salts with lecithin,
286 it is hypothesised that the use of an MLC system that combines the use of an APS column with
287 bile salts with lecithin as a mobile phase would provide a more reliable HIA predictive model
288 covering a wider range of %HIA prediction.



289



290
291
292 **Figure 2:** Residual plot for optimal logit HIA regression model.
293
294



307



308
309
310
311
312
313
314 **Figure 3:** Partial regression plots of experimental logit HIA. values against $\log P_{mw}$, V_M and S_w .
315
316

317

318

319

Table 1: Experimental and predicted values for %HIA.

Drug	Expt. %HIA	Pred. %HIA	Reference
Acetaminophen	95.00	94.82 (± 0.04)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Acetylsalicylic acid	82.00	87.00 (± 0.04)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Caffeine	99.00	98.42 (± 0.01)	(Yan, Wang et al. 2008)
Carbamazepine	70.00	73.53 (± 0.09)	(Varma, Sateesh et al. 2005)
Cimetidine*	73.50	73.60 (± 0.05)	(Veber, Johnson et al. 2002; Yan, Wang et al. 2008)
Diclofenac	90.00	90.73 (± 0.01)	(Molero-Monfort, Escuder-Gilabert et al. 2001)
Fenoprofen*	85.00	93.07 (± 0.06)	(Hou, Wang et al. 2007)
Fluconazole	97.50	98.29 (± 0.05)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Flurbiprofen	92.00	84.68 (± 0.01)	(Raevsky 2004)
Gemfibrozil	95.00	96.57 (± 0.05)	(Paixão, Gouveia et al. 2012)
Ibuprofen	85.00	90.25 (± 0.01)	(Paixão, Gouveia et al. 2012)
Indomethacin	99.00	98.22 (± 0.04)	(Chu 2009)
Ketoprofen	96.00	92.94 (± 0.05)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Lidocaine	95.00	96.30 (± 0.02)	(Molero-Monfort, Escuder-Gilabert et al. 2001; Chu 2009)
Lornoxicam*	100.00	88.67 (± 0.06)	(Newby, Freitas et al. 2015)
Meloxicam	90.00	92.40 (± 0.06)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Naproxen	94.00	91.02 (± 0.05)	(Castillo-Garit, Cañizares-Carmenate et al. 2014)
Nicotinic acid*	94.00	100.00 (± 0.01)	(Yan, Wang et al. 2008)
Phenylbutazone	98.00	98.36 (± 0.01)	(Hou, Wang et al. 2007)
Piroxicam*	99.00	92.28 (± 0.05)	(Chu 2009)
Salicylic acid*	99.00	75.44 (± 0.08)	(Raevsky 2004)
Theophylline	98.00	98.24 (± 0.01)	(Kansy, Senner et al. 1998)
Terbutaline*	80.00	84.25 (± 0.01)	(Grès, Julian et al. 1998)

The asterisk (*) indicates the validation compounds.




Figure 4: Plot of experimental vs. predicted %HIA.

323

324

325

326 **4. Conclusion:**

327 The change in the type of the stationary phase used in the MLC method from cyanopropyl to
 328 aminopropyl (APS) had a significant impact on the interaction of the analysed drugs with both
 329 the micellar mobile phase and the stationary phase used and consequently on their elution. This
 330 method was able to predict %HIA using a reliable model. This MLC method has one major
 331 advantage over that previously published with a different column in that it permits analysis of
 332 a greater number of compounds than that analysed prior to this study. This is because some
 333 compounds displayed non-binding behaviour in the previously published method (i.e. it was
 334 not possible to calculate $\log P_{mw}$ for these compounds) yet they displayed binding or
 335 antibinding behaviour using this method. This expanded study helps in the establishment of a
 336 reliable model for prediction of HIA from a wider dataset. It is hypothesised that by combining
 337 the physiologically relevant mixture of bile salts that displayed good HIA predictability with
 338 the column used in this study ($R^2_{pred.}=81\%$) could create a mathematical model with an even
 339 higher predictive ability that could be developed based on a greater number of compounds in
 340 both the training and validation sets.

341

342 **References:**

- 343 **Anslyn, E. V. and D. A. Dougherty (2006). Modern physical organic chemistry, University Science**
 344 **Books.**
- 345 **Arunyanart, M. and L.J.Cline-Love (1984). "Model of micellar effects on liquid chromatography**
 346 **capacity factors and for determination for micelle solute equilibrium constants". Anal.**
 347 **Chem. 56: 1557–1561.**
- 348 **Berthod, A. and C. Garcia-Alvarez-Coque (2000). Micellar liquid chromatography, CRC Press.**
- 349 **Castillo-Garit, J., Y. Cañizares-Carmenate, et al. (2014). "Prediction of ADME properties, part 1:**
 350 **classification models to predict Caco-2 cell permeability using atom-based bilinear**
 351 **indices." Afinidad 71(566): 129-138.**

352 Chu, K. A. (2009). "Predicting Passive Intestinal Drug Absorption: An Interesting Relationship
353 between Fraction Absorbed and Melting Point." The University of Arizona, Tucson, AZ;
354 Escuder-Gilabert, L., J. Martinez-Pla, et al. (2003). "Biopartitioning micellar separation methods:
355 modelling drug absorption." Journal of Chromatography B 797(1): 21-35.
356 Escuder-Gilabert, L., M. Molero-Monfort, et al. (2004). "Potential of biopartitioning micellar
357 chromatography as an in vitro technique for predicting drug penetration across the blood-
358 brain barrier." Journal of Chromatography B 807(2): 193-201.
359 Gama, M. R., R. G. da Costa Silva, et al. (2012). "Hydrophilic interaction chromatography." TrAC
360 Trends in Analytical Chemistry 37: 48-60.
361 Grès, M.-C., B. Julian, et al. (1998). "Correlation between oral drug absorption in humans, and
362 apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison
363 with the parental Caco-2 cell line." Pharmaceutical research 15(5): 726-733.
364 Hou, T., J. Wang, et al. (2007). "ADME evaluation in drug discovery. 7. Prediction of oral
365 absorption by correlation and classification." Journal of chemical information and
366 modeling 47(1): 208-218.
367 <http://www.chemspider.com/> (December, 2018).
368 Kalyankar, T., P. Kulkarni, et al. (2014). "Applications of Micellar Liquid Chromatography in
369 Bioanalysis: A Review." Journal of Applied Pharmaceutical Science 4(1): 128-134.
370 Kanakaiah, B. (2013). "Micellar Liquid Chromatography." International Journal of Bio-Pharma
371 Research 2(04): 117-122.
372 Kansy, M., F. Senner, et al. (1998). "Physicochemical high throughput screening: parallel artificial
373 membrane permeation assay in the description of passive absorption processes." Journal
374 of medicinal chemistry 41(7): 1007-1010.
375 Martín-Biosca, Y., M. Molero-Monfort, et al. (2003). "Rapid in vitro test to predict ocular tissue
376 permeability based on biopartitioning micellar chromatography." European journal of
377 pharmaceutical sciences 20(2): 209-216.
378 Milošević, N.P., S.Z. Stojanović, K. Penov-Gaši, N. Perišić-Janjić, R. Kaliszan (2014) "Reversed- and
379 normal-phase liquid chromatography in quantitative structure retention-property
380 relationships of newly synthesized seco-androstene derivatives." Journal of
381 Pharmaceutical and Biomedical Analysis 88: 636-642.
382 Molero-Monfort, M., L. Escuder-Gilabert, et al. (2001). "Biopartitioning micellar chromatography:
383 an in vitro technique for predicting human drug absorption." Journal of Chromatography
384 B: Biomedical Sciences and Applications 753(2): 225-236.
385 Newby, D., A. A. Freitas, et al. (2015). "Decision trees to characterise the roles of permeability and
386 solubility on the prediction of oral absorption." European Journal of Medicinal Chemistry
387 90: 751-765.
388 Norinder, U., T. Österberg, et al. (1999). "Theoretical calculation and prediction of intestinal
389 absorption of drugs in humans using MolSurf parametrization and PLS statistics." European journal of pharmaceutical sciences 8(1): 49-56.
390 Olesen, N. E., P. Westh, et al. (2015). "Determination of thermodynamic potentials and the
391 aggregation number for micelles with the mass-action model by isothermal titration
392 calorimetry: A case study on bile salts." Journal of colloid and interface science 453: 79-89.
393 Olsen, B. A. (2001). "Hydrophilic interaction chromatography using amino and silica columns for
394 the determination of polar pharmaceuticals and impurities." Journal of chromatography A
395 913(1-2): 113-122.
396 Paixão, P., L. F. Gouveia, et al. (2012). "Prediction of the human oral bioavailability by using in
397 vitro and in silico drug related parameters in a physiologically based absorption model." International journal of pharmaceuticals 429(1): 84-98.
398 Pramauro, E., C. Minero, et al. (1988). "Partition equilibria of phenols between water and anionic
399 micelles: Correlation with the octanol/water system." Analytica Chimica Acta 212: 171-
400 180.
401
402

- 403 Raevsky, O. A. (2004). "Physicochemical descriptors in property-based drug design." Mini reviews
404 in medicinal chemistry 4(10): 1041-1052.
- 405 Raevsky, O. A., V. I. Fetisov, et al. (2000). "Quantitative Estimation of Drug Absorption in Humans
406 for Passively Transported Compounds on the Basis of Their Physico-chemical Parameters."
407 Quantitative Structure-Activity Relationships 19(4): 366-374.
- 408 Rambla-Alegre, M. (2012). "Basic principles of MLC." Chromatography Research International
409 2012: Article ID 898520.
- 410 Rambla-Alegre, M., S. Carda-Broch, et al. (2009). "Column classification and selection for the
411 determination of antibiotics by micellar liquid chromatography." Journal of Liquid
412 Chromatography & Related Technologies® 32(8): 1127-1140.
- 413 Shokry, D. S., L. J. Waters, et al. (2018). "Incorporating physiologically relevant mobile phases in
414 micellar liquid chromatography for the prediction of human intestinal absorption."
415 Biomedical Chromatography 32(12) 1-9.
- 416 Smith, D. A., H. Waterbeemd, D. K. Walker, et al. (2006). "Pharmacokinetics and metabolism in
417 drug design." Methods and principles in medicinal chemistry 31: 8.
- 418 Takeuchi, T., J. Chu, et al. (1998). "Bile acids as stationary phase in liquid chromatography."
419 Chromatographia 47(3-4): 183-188.
- 420 Varma, M. V., K. Sateesh, et al. (2005). "Functional role of P-glycoprotein in limiting intestinal
421 absorption of drugs: contribution of passive permeability to P-glycoprotein mediated
422 efflux transport." Molecular pharmaceutics 2(1): 12-21.
- 423 Veber, D. F., S. R. Johnson, et al. (2002). "Molecular properties that influence the oral
424 bioavailability of drug candidates." Journal of medicinal chemistry 45(12): 2615-2623.
- 425 Waters, L. J., Y. Shahzad, et al. (2013). "Modelling skin permeability with micellar liquid
426 chromatography." European Journal of Pharmaceutical Sciences 50(3): 335-340.
- 427 Waters, L. J., D. S. Shokry, et al. (2016). "Predicting human intestinal absorption in the presence of
428 bile salt with micellar liquid chromatography." Biomedical Chromatography 30(10): 1618-
429 1624.
- 430 Yan, A., Z. Wang, et al. (2008). "Prediction of human intestinal absorption by GA feature selection
431 and support vector machine regression." International journal of molecular sciences 9(10):
432 1961-1976.
- 433 Zhao, Y. H., M. H. Abraham, et al. (2002). "Rate-limited steps of human oral absorption and QSAR
434 studies." Pharmaceutical research 19(10): 1446-1457.

435

436

437